Viking Therapeutics (VKTX) Operating Expenses (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Operating Expenses data on file, last reported at $164.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 195.89% year-over-year to $164.1 million; the trailing twelve-month figure through Mar 2026 stood at $502.0 million (up 191.32% YoY), and the FY2025 full-year result was $393.3 million, up 160.63% from the prior year.
• Operating Expenses held at $164.1 million in Q1 2026, from $164.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $164.7 million in Q4 2025 to a low of $16.2 million in Q3 2022.
• A 5-year average of $51.7 million and a median of $34.1 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses increased 13.45% in 2022 and jumped 256.28% in 2025, its largest moves.
• Tracing VKTX's Operating Expenses over 5 years: stood at $20.3 million in 2022, then jumped by 44.38% to $29.3 million in 2023, then soared by 57.89% to $46.2 million in 2024, then jumped by 256.28% to $164.7 million in 2025, then decreased by 0.37% to $164.1 million in 2026.
• Business Quant data shows VKTX's Operating Expenses at $164.1 million in Q1 2026, $164.7 million in Q4 2025, and $98.6 million in Q3 2025.